AUTO-1/22 by Autolus Therapeutics for Hairy Cell Leukemia: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AUTO-1/22 overview
AUTO-1NG is under development for the treatment of relapsed or refractory acute lymphoblastic leukemia, Burkitt lymphoma, acute myelocytic leukemia (AML, acute myeloblastic leukemia), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML, chronic myeloid leukemia), hairy cell leukemia, Hodgkin lymphoma (B-cell Hodgkin lymphoma) in pediatrics. It is a chimeric antigen receptor (CAR) T cell therapy comprising of CD19 CAR of AUTO-1 and a novel CD22 CAR. The drug candidate acts by targeting CD19 and CD22 expressing cancer cells.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Autolus Therapeutics overview
Autolus Therapeutics (Autolus), formerly Autolus Therapeutics is a clinical-stage biopharmaceutical company. It offers programmed T cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products includes Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. It has also developed proprietary viral vector and semi-automated cell manufacturing processes, which are used in clinical-stage programs. The company collaborates with leading academic institutions and industry partners to develop and deliver programmed T cell product candidates for cancer patients. Autolus is headquartered in London, Greater London, the UK.
For a complete picture of AUTO-1/22’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#AUTO122 #Autolus #Therapeutics #Hairy #Cell #Leukemia #Likelihood #Approval
